472 Federal Register / Vol. 89, No. 3 / Thursday, January 4, 2024 / Notices 

1See https://www.federalregister.gov/documents/ 

2023/09/29/2023-21514/notice-of-request-forpublic-comments-on-a-draft-recommendation-toupdate-the-hrsa-supported-womens. 

B. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414. 

Comments can also be sent 

electronically to 

Comments.applications@chi.frb.org: 

1. First Busey Corporation, 

Champaign, Illinois; to merge with 

Merchants and Manufacturers Bank 

Corporation, Channahon, Illinois, and 

thereby indirectly acquire Merchants 

and Manufacturers Bank, Joliet, Illinois. 

C. Federal Reserve Bank of St. Louis 

(Holly A. Rieser, Senior Manager) P.O. 

Box 442, St. Louis, Missouri 63166– 

2034. Comments can also be sent 

electronically to 

Comments.applications@stls.frb.org: 

1. Old National Bancorp, Evansville, 

Indiana; to merge with CapStar 

Financial Holdings, Inc., and thereby 

indirectly acquire CapStar Bank, both of 

Nashville, Tennessee. 

Board of Governors of the Federal Reserve 

System. 

Ann E. Misback, 

Secretary of the Board. 

[FR Doc. 2023–28966 Filed 1–3–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Update to the Health Resources and 

Services Administration-Supported 

Women’s Preventive Services 

Guidelines Relating to Screening for 

Urinary Incontinence 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: A Federal Register notice 

published on September 29, 2023, 

detailed and sought public comment on 

recommendations under development 

by the Women’s Preventive Services 

Initiative (WPSI), regarding updates to 

the HRSA-supported Women’s 

Preventive Services Guidelines 

(Guidelines). The proposed updates 

specifically related to Screening for 

Urinary Incontinence. WPSI convenes 

health professionals to develop draft 

recommendations for HRSA’s 

consideration. Two public comments 

were received and considered as 

detailed below. On December 28, 2023, 

HRSA accepted as final WPSI’s 

recommended updates to the Screening 

for Urinary Incontinence guideline. 

Under applicable law, nongrandfathered group health plans and 

health insurance issuers offering nongrandfathered group and individual 

health insurance coverage must include 

coverage, without cost sharing, for 

certain preventive services, including 

those provided for in the HRSAsupported Guidelines. The Departments 

of Labor, Health and Human Services, 

and the Treasury have previously issued 

regulations describing how group health 

plans and health insurance issuers 

apply the coverage requirements. Please 

see https://www.hrsa.gov/womensguidelines for additional information. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly Sherman, HRSA, Maternal 

and Child Health Bureau, telephone: 

(301) 443–8283, email: wellwomancare@

hrsa.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Patient Protection and Affordable Care 

Act, Public Law 111–148, the preventive 

care and screenings set forth in the 

Guidelines are required to be covered 

without cost-sharing by certain group 

health plans and health insurance 

issuers. HRSA established the 

Guidelines in 2011 based on expert 

recommendations by the Institute of 

Medicine, now known as the National 

Academy of Medicine, developed under 

a contract with the Department of 

Health and Human Services. Since 

2016, HRSA has funded cooperative 

agreements with the American College 

of Obstetricians and Gynecologists for 

the Women’s Preventive Services 

Initiative (WPSI) to convene a coalition 

representing clinicians, academics, and 

consumer-focused health professional 

organizations to conduct a rigorous 

review of current scientific evidence, 

solicit and consider public input, and 

make recommendations to HRSA 

regarding updates to the Guidelines to 

improve adult women’s health across 

the lifespan. HRSA then determines 

whether to support, in whole or in part, 

the recommended updates to the 

Guidelines. 

WPSI includes an Advisory Panel and 

two expert committees, the 

Multidisciplinary Steering Committee 

and the Dissemination and 

Implementation Steering Committee, 

which are comprised of a broad 

coalition of organizational 

representatives who are experts in 

disease prevention and women’s health 

issues. With oversight by the Advisory 

Panel, and with input from the 

Multidisciplinary Steering Committee, 

WPSI examines the evidence to develop 

new (and update existing) 

recommendations for women’s 

preventive services. WPSI’s 

Dissemination and Implementation 

Steering Committee takes HRSAapproved recommendations and 

disseminates them through the 

development of implementation tools 

and resources for both patients and 

practitioners. 

WPSI bases its recommended updates 

to the Guidelines on review and 

synthesis of existing clinical guidelines 

and new scientific evidence, following 

the National Academy of Medicine 

standards for establishing foundations 

for and rating strengths of 

recommendations, articulation of 

recommendations, and external reviews. 

Additionally, HRSA requires that WPSI 

incorporate processes to assure 

opportunity for public comment, 

including participation by patients and 

consumers, in the development of the 

updated Guidelines. 

WPSI proposed and HRSA has 

accepted recommended updates to the 

Guideline relating to Screening for 

Urinary Incontinence, which now reads, 

‘‘The Women’s Preventive Services 

Initiative recommends screening women 

for urinary incontinence annually. 

Screening should assess whether 

women experience urinary incontinence 

and whether it impacts their activities 

and quality of life. If indicated, 

facilitating further evaluation and 

treatment is recommended.’’ 

Discussion of Recommended Updated 

Guideline Relating to Screening for 

Urinary Incontinence: WPSI 

recommended minor updates to the 

previous Guideline language. The first 

change is removal of the word ‘‘ideally’’ 

from the second sentence, for clarity. 

Removal of the word ‘‘ideally’’ does not 

substantively change the Guideline. The 

second change is in the final sentence, 

changing the word ‘‘referring’’ to 

‘‘facilitating’’ to reflect that clinicians in 

practice, after screening for urinary 

incontinence, may decide to treat or 

manage urinary incontinence as part of 

standard primary care services or refer 

to specialists if specialist care is needed. 

The change in language from ‘‘referring’’ 

to ‘‘facilitating’’ does not substantively 

change the Guideline. Lastly, WPSI 

recommended minor editorial revisions 

to the language of the Guideline, for 

clarity. These minor editorial revisions 

have no substantive effect on the 

Guideline. 

A Federal Register notice published 

on September 29, 2023, sought public 

comment on these proposed updates (88 

FR 67318).1 WPSI considered all public 

comments as part of its deliberative 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 3 / Thursday, January 4, 2024 / Notices 473 

process and provided the comments to 

HRSA for its consideration. Two 

respondents provided comments during 

the public comment period. One 

commenter suggested improving 

reimbursement by including billing 

codes for screening and counseling. 

This comment falls outside the scope of 

the Guidelines. The other commenter 

suggested adding the word ‘‘comorbidities’’ to a WPSI list of potential 

research topics. This comment was not 

accepted as it does not address the 

recommendation itself, but rather 

supporting materials. 

After consideration of public 

comment, WPSI submitted the 

recommended updates for Screening for 

Urinary Incontinence as detailed above. 

On December 28, 2023, the HRSA 

Administrator accepted WPSI’s 

recommendations and, as such, updated 

the Women’s Preventive Services 

Guidelines. Non-grandfathered group 

health plans and health insurance 

issuers offering group or individual 

health insurance coverage must cover 

without cost-sharing the services and 

screenings listed on the updated 

Women’s Preventive Services 

Guidelines for plan years (in the 

individual market, policy years) that 

begin 1 year after this date. Thus, for 

most plans, this update will take effect 

for purposes of the Section 2713 

coverage requirement in 2025. 

Additional information regarding the 

Women’s Preventive Services 

Guidelines can be accessed at the 

following link: https://www.hrsa.gov/ 

womens-guidelines. 

Authority: Section 2713(a)(4) of the 

Public Health Service Act, 42 U.S.C. 

300gg–13(a)(4). 

Carole Johnson, 

Administrator. 

[FR Doc. 2023–28970 Filed 1–3–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Vaccine Injury Compensation 

Program; List of Petitions Received 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HRSA is publishing this 

notice of petitions received under the 

National Vaccine Injury Compensation 

Program (the Program), as required by 

the Public Health Service (PHS) Act, as 

amended. While the Secretary of HHS is 

named as the respondent in all 

proceedings brought by the filing of 

petitions for compensation under the 

Program, the United States Court of 

Federal Claims is charged by statute 

with responsibility for considering and 

acting upon the petitions. 

FOR FURTHER INFORMATION CONTACT: For 

information about requirements for 

filing petitions, and the Program in 

general, contact Lisa L. Reyes, Clerk of 

Court, United States Court of Federal 

Claims, 717 Madison Place NW, 

Washington, DC 20005, (202) 357–6400. 

For information on HRSA’s role in the 

Program, contact the Director, National 

Vaccine Injury Compensation Program, 

5600 Fishers Lane, Room 08W–25A, 

Rockville, Maryland 20857; 1–800–338– 

2382, or visit our website at: http://

www.hrsa.gov/vaccinecompensation/ 

index.html. 

SUPPLEMENTARY INFORMATION: The 

Program provides a system of no-fault 

compensation for certain individuals 

who have been injured by specified 

childhood vaccines. Subtitle 2 of title 

XXI of the PHS Act, 42 U.S.C. 300aa– 

10 et seq., provides that those seeking 

compensation are to file a petition with 

the United States Court of Federal 

Claims and to serve a copy of the 

petition to the Secretary of HHS, who is 

named as the respondent in each 

proceeding. The Secretary has delegated 

this responsibility under the Program to 

HRSA. The Court is directed by statute 

to appoint special masters who take 

evidence, conduct hearings as 

appropriate, and make initial decisions 

as to eligibility for, and amount of, 

compensation. 

A petition may be filed with respect 

to injuries, disabilities, illnesses, 

conditions, and deaths resulting from 

vaccines described in the Vaccine Injury 

Table (the table) set forth at 42 CFR 

100.3. This table lists for each covered 

childhood vaccine the conditions that 

may lead to compensation and, for each 

condition, the time period for 

occurrence of the first symptom or 

manifestation of onset or of significant 

aggravation after vaccine 

administration. Compensation may also 

be awarded for conditions not listed in 

the table and for conditions that are 

manifested outside the time periods 

specified in the table, but only if the 

petitioner shows that the condition was 

caused by one of the listed vaccines. 

Section 2112(b)(2) of the PHS Act, 42 

U.S.C. 300aa–12(b)(2), requires that 

‘‘[w]ithin 30 days after the Secretary 

receives service of any petition filed 

under section 2111 the Secretary shall 

publish notice of such petition in the 

Federal Register.’’ Set forth below is a 

list of petitions received by HRSA on 

November 1, 2023, through November 

30, 2023. This list provides the name of 

the petitioner, city, and state of 

vaccination (if unknown then the city 

and state of the person or attorney filing 

the claim), and case number. In cases 

where the Court has redacted the name 

of a petitioner and/or the case number, 

the list reflects such redaction. 

Section 2112(b)(2) also provides that 

the special master ‘‘shall afford all 

interested persons an opportunity to 

submit relevant, written information’’ 

relating to the following: 

1. The existence of evidence ‘‘that 

there is not a preponderance of the 

evidence that the illness, disability, 

injury, condition, or death described in 

the petition is due to factors unrelated 

to the administration of the vaccine 

described in the petition,’’ and 

2. Any allegation in a petition that the 

petitioner either: 

a. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition not set forth in the 

Vaccine Injury Table but which was 

caused by’’ one of the vaccines referred 

to in the table, or 

b. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition set forth in the 

Vaccine Injury Table the first symptom 

or manifestation of the onset or 

significant aggravation of which did not 

occur within the time period set forth in 

the Table but which was caused by a 

vaccine’’ referred to in the table. 

In accordance with section 2112(b)(2), 

all interested persons may submit 

written information relevant to the 

issues described above in the case of the 

petitions listed below. Any person 

choosing to do so should file an original 

and three (3) copies of the information 

with the Clerk of the United States 

Court of Federal Claims at the address 

listed above (under the heading FOR

FURTHER INFORMATION CONTACT), with a 

copy to HRSA addressed to Director, 

Division of Injury Compensation 

Programs, Health Systems Bureau, 5600 

Fishers Lane, 08W–25A, Rockville, 

Maryland 20857. The Court’s caption 

(Petitioner’s Name v. Secretary of HHS) 

and the docket number assigned to the 

petition should be used as the caption 

for the written submission. Chapter 35 

of title 44, United States Code, related 

to paperwork reduction, does not apply 


khammond on DSKJM1Z7X2PROD with NOTICES